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Background
β2-Adrenergic receptor agonists accelerate resolution of 
pulmonary edema in experimental and clinical studies of 
acute lung injury (ALI).
Methods
Objective: To determine whether an aerosolized β2-
agonist would improve clinical outcomes in patients with 
ALI.
Design: Multi-center, phase III randomized, placebo-
controlled clinical trial.
Setting: 33 hospitals participating National Heart, Lung, 
and Blood Institute Acute Respiratory Distress Syndrome 
(ARDS) Clinical Trials Network.
Subjects: Patients who were intubated and receiving 
mechanical ventilation, had bilateral inﬁ ltrates consistent 
with edema on frontal chest radiograph, had a ratio of 
PaO2 to FIO2 (fraction of inspired oxygen) of 300 or less, 
and not had clinical evidence of left atrial hypertension. 
A maximum enrolment of 1,000 patients was planned.
Intervention: Patients were randomized to receive 
aerosolized albuterol (5  mg) or saline placebo every 
4 hours for up to 10 days.
Outcomes: Th e primary outcome variable was ventilator-
free days (VFD). Secondary outcome measures included 
mortality before hospital discharge on day 60 and day 90, 
the number of intensive care unit (ICU)-free days and the 
number of organ failure-free days.
Results
Th ere were 282 patients enrolled before the trial was 
stopped for futility after the second interim analysis. Th e 
VFDs diﬀ erence with albuterol treatment was un-
favourable by -2.2 days, well past the futility boundary of 
-0.4 VFDs. VFDs were not signiﬁ cantly diﬀ erent between 
the albuterol and placebo groups (means of 14.4 and 
16.6  days, respectively; 95% conﬁ dence interval for the 
diﬀ erence, -4.7 to 0.3  days; P  =  0.087). Rates of death 
before hospital discharge and the number of organ 
failure-free days were also not signiﬁ cantly diﬀ erent 
between the two groups. Th e number of ICU-free days 
was lower in the albuterol group in comparison with the 
placebo group (means of 13.5 and 16.2 days respectively; 
95% conﬁ dence intervals for the mean diﬀ erence, -4.9 to 
-0.4  days; P  =  0.023). Overall, heart rates were signiﬁ -
cantly higher in the albuterol group by approximately 
5  beats/minute in the ﬁ rst 2  days after randomization 
(P < 0.05), but rates of new onset atrial ﬁ brillation (10% in 
both groups) and other cardiac dysrhythmias were not 
signiﬁ cantly diﬀ erent.
Conclusions
Th ese results suggest that aerosolized albuterol does not 
improve clinical outcomes in ALI patients. Routine use of 
β2 agonist therapy in mechanically ventilated ALI patients 
cannot be recommended.
Commentary
Acute Lung Injury (ALI) is a major cause of respiratory 
failure and accounts for signiﬁ cant mortality in critically 
ill patients [1]. Th e pathophysiology of ALI involves a 
pro-inﬂ ammatory state with increased permeability and 
ﬂ uid leakage into the alveoli and interstitium, resulting in 
pulmonary edema and impaired gas exchange. Th e 
resolution of alveolar edema is a key factor in recovery © 2010 BioMed Central Ltd
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from ALI and has therefore been the subject of a sub-
stantial number of experimental studies. Many of these 
studies demonstrate that transportation of sodium and 
chloride across the alveolar epithelial cells, which can be 
achieved by increased exogenous cyclic AMP stimulation 
with β2 adrenergic agonists, is one of the principal 
mechanisms in alveolar ﬂ uid clearance [2]. In an ex vivo 
human lung model, alveolar ﬂ uid clearance doubled with 
use of a β2 adrenergic receptor agonist [3]. Furthermore, 
a single center, phase II randomized trial (BALTI study) 
showed that patients with ALI receiving an intravenous 
β2 adrenergic agonist had lower lung water, lower plateau 
airway pressures and lower Murray lung injury scores [4]. 
Th ese laboratory and early clinical data showed promis-
ing results to suggest a potential therapeutic role of β2 
adrenergic agonists in improving clinical outcomes when 
used routinely in patients with ALI.
Based on this preliminary work, the Acute Respiratory 
Distress Syndrome (ARDS) Clinical Trials Network 
conducted the ALTA study [5]. ALTA was the ﬁ rst multi-
center, phase III randomized study to test the role of 
routine use of a β2 adrenergic agonist in improving clini-
cal outcomes in patients with ALI. Th e primary outcome 
measure for this study was the number of ventilator free 
days (VFDs) by day 28. Th e trial was terminated prema-
turely after recruitment of only 282 patients of the 
proposed 1,000 patients at the second interim analysis on 
grounds of futility. Th e primary outcome, the number of 
VFDs to day  28, was not signiﬁ cantly diﬀ erent between 
study groups. Mortality before hospital discharge to 
days 60 and 90 and the number of organ failure-free days 
were also not signiﬁ cantly diﬀ erent between the two 
groups. Th e number of intensive care unit-free days was 
lower in the albuterol-treated group, suggesting that sur-
vivors receiving albuterol spent more time in the ICU 
than survivors receiving placebo. Also noted was that the 
albuterol-treated group had a higher heart rate and a 
tendency towards more ﬂ uid resuscitation. Th e Kaplan-
Meier survivor curves suggested worse survival in 
patients who routinely received albuterol compared to 
placebo, although the statistical signiﬁ cance of this 
analysis was not reported.
Th ere are several potential reasons why β2 adrenergic 
agonists failed to improve outcomes in this study, despite 
promising physiological evidence. Among these are the 
possible lack of signiﬁ cant drug delivery to the aerated, 
nonedematous lung; the presence of injured alveolar epi-
thelium unable to clear lung water; and down-regulation 
of β2 adrenergic receptors with continued use of β2 
adrenergic agonist. Under these scenarios, the β2 adre-
nergic agonists would fail to achieve their intended eﬀ ect 
in real-life clinical settings.
Another possibility is that β2 adrenergic agonist might 
successfully improve lung water clearance but harm 
patients in other ways. For example, β2 adrenergic 
agonists cause tachycardia which might lead to greater 
ﬂ uid resuscitation in the study drug arm. Th is was seen in 
ALTA, where patients in the β2 adrenergic agonist arm 
experi enced higher heart rates and a trend towards 
higher cumulative ﬂ uid balance in the albuterol-treated 
arm, particularly on day  2 after randomization. β2 adre-
nergic agonists might also lead to lactic acidosis and cardiac 
arrhythmias, as were noted in another recent randomized 
controlled trial stopped early for potential harm [6].
Along these lines, this clinical trial provides an 
important caveat to our use of surrogate endpoints to 
guide clinical therapy in the intensive care unit. Surrogate 
endpoints such as oxygenation and lung water measure-
ments are valid only when they are causally-related to a 
patient-centered outcome (i.e. mortality), and there is no 
other link between the therapy of interest and the 
patient-centered outcomes [7]. Our ﬁ eld has been burned 
before, with numerous examples of therapies that im-
proved surrogate outcomes but when studied in large 
trials ultimately were found to harm patients [8]. Of 
course, physiology is and will always be an important 
component of clinical decision making in the ICU. How-
ever, we must remember that when we make decisions 
based on physiological rationale alone, we may harm our 
patients.
With regards to β2 adrenergic agonists in ALI, there is 
additional cause for concern. β2 adrenergic agonists are 
among the most commonly prescribed medications for 
mechanically ventilated patients in the ICU. Often they 
are prescribed routinely, regardless of evidence of signi ﬁ -
cant airﬂ ow obstruction or intrinsic positive end-
expiratory pressure. In these cases, we may truly be 
causing harm in the absence of beneﬁ t. Th e ALTA study 
reminds us that no drug in the ICU is completely benign. 
Although this study certainly does not provide evidence 
precluding the use of inhaled β2 adrenergic agonists in 
the ICU, any routine use in the absence of demonstrated 
airﬂ ow obstruction should be reconsidered.
Recommendation
Whenever we use surrogate endpoints and physiologic 
rationale to make decisions in patient care, investigators 
and clinicians should be cautious when translating the 
data into clinical beneﬁ t. As seen from this study, routine 
use of β2 adrenergic agonist in ALI cannot be recom-
mended, since there was no beneﬁ t and a suggestion of a 
tendency to cause harm to patients. β2 adrenergic agonist 
therapy could be used as a therapeutic agent for use in 
patients with ALI and evidence of air ﬂ ow obstruction, 
but not on a routine basis.
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